Drug Trial Radar · NCT03329508
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
Last checked: Nov 20, 2026Latest source record: Mar 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
544
Actual
Start
Jan 19, 2018
Primary completion
Aug 23, 2021
Study completion Oct 31, 2021
Sponsor
- Lead sponsor
- Pharma Two B Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson's disease. The two drugs work in two different mechanisms that help each other, so there is a reason to believe that their combined activity will be better than each individual drug, and that lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs, in an improved formulation, that is hoped to be more effective in controlling Parkinson's disease symptoms and with less side effects than each of the drugs taken alone or the current available commercial drugs taken together. In a previously completed clinical trial a significant improvement in Parkinson's disease symptoms was seen in patients treated with P2B001 compared to patients that were treated with placebo. In this phase 3 study , the safety and efficacy of P2B001 will be assessed by comparing P2B001 to its individual components pramipexole and rasagiline. This will be done by monitoring the motor and non-motor symptoms, evaluating responses participants provide on questionnaires relating to Parkinson's disease and quality of life that will be completed on every visit. In addition, this study will also compare P2B001 to a marketed drug of pramipexole ER. Approximately 525 patients will participate in this research study and the participation in this study will last between 14 to 18 weeks.
Conditions
- Parkinson Disease
- Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mgDrug
Fixed low dose extended release combination capsule of pramipexole and rasagiline
Rasagiline 0.75 mgDrug
Rasagiline 0.75 mg oral extended release capsule, component
Pramipexole 0.6 mgDrug
Pramipexole 0.6 mg oral extended release capsule, component
Marketed Pramipexole ERDrug
Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160).Time frame: baseline to week 12
Locations
72 sites in 4 countries. Site status is shown where the registry gives one.
P2B001/003 Site Scottsdale
Scottsdale, Arizona
P2B001/003 study site Scottsdale
Scottsdale, Arizona
P2B001/003 Study site little Rock
Little Rock, Arkansas
P2B001 site Los Angeles
Los Angeles, California
P2B001 Study site Englewood,
Englewood, Colorado
P2B001 Study Vernon
Vernon, Connecticut
P2B001/003 site Boca Raton
Boca Raton, Florida
P2B001/003 Site Boca Raton
Boca Raton, Florida
P2B001/003 study site Jacksonville
Jacksonville, Florida
P2B001/003 site Miami
Miami, Florida
P2B001/003 Site Port Charlotte
Port Charlotte, Florida
P2B001/003 Site Sarasota
Sarasota, Florida
P2B001/003 Site Tampa
Tampa, Florida
P2B001/003 Site Augusta
Augusta, Georgia
P2B001/003 study site Honolulu
Honolulu, Hawaii
P2B001/003 site Chicago
Chicago, Illinois
P2B001/003 Site Winfield
Winfield, Illinois
P2B001/003 site Kansas City
Kansas City, Kansas
P2B001/003 Site Lexington
Lexington, Kentucky
P2B001/003 study site Boston
Boston, Massachusetts
P2B001/003 Site East Lansing
East Lansing, Michigan
P2B001/003 study site west Bloomfield
West Bloomfield, Michigan
P2B001/003 Site Golden Valley
Golden Valley, Minnesota
P2B001/003 site St. Louis
St Louis, Missouri
P2B001/003 study site New Hampshire
Lebanon, New Hampshire
P2B001/003 Study site Camden
Camden, New Jersey
P2B001 Study site Edison
Edison, New Jersey
P2B001/003 Study site Albuquerque
Albuquerque, New Mexico
P2B001/003 Study site Brooklyn
Brooklyn, New York
P2B001/003 Site Commack
Commack, New York
P2B001/003 New York
New York, New York
P2B001 Study site Syracuse
Syracuse, New York
P2B001/003 Study site Williamsville
Williamsville, New York
P2B001/003 Site Asheville
Asheville, North Carolina
P2B001 study site Cincinnati
Cincinnati, Ohio
P2B001/003 Site Toledo
Toledo, Ohio
P2B001/003 Study site Hershey
Hershey, Pennsylvania
P2B001/003 Greenville
Greenville, South Carolina
P2B0011/003 Study Veracity Neuroscience
Memphis, Tennessee
p2B001/003 Study site Memphis
Memphis, Tennessee
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.